RNF185 promotes esophageal squamous cell carcinoma progression by regulating BAK1 ubiquitination and activating the...

RNF185 is a mitochondrial RING-type E3 ubiquitin ligase known to regulate mitochondrial homeostasis, apoptosis, and innate immune signaling through ubiquitination of substrates such as BNIP1, JWA, and cGAS. Although dysregulation of RNF185 has been reported in several cancers, its role in esophageal squamous cell carcinoma (ESCC) remains unclear. The present study aimed to investigate the function of RNF185 in ESCC progression and assess its potential as a therapeutic target.

We analyzed RNF185 expression in the TCGA-ESCA dataset and ESCC cell lines. RNF185 knockout cell lines were generated using CRISPR/Cas9. Functional assays including CCK-8, colony formation, apoptosis analysis, transmission electron microscopy (TEM), and ELISA were performed. Activation of the cGAS-STING pathway and downstream transcription factors was assessed by Western blot, qPCR, luciferase assays, and ChIP-qPCR. BAK1 ubiquitination and interaction with RNF185 were evaluated using immunoprecipitation. In vivo tumor growth inhibition was tested using a subcutaneous mouse xenograft model with Honokiol treatment.

RNF185 was significantly overexpressed in ESCC tissues and correlated with worse patient outcomes. RNF185 knockout suppressed cell proliferation, induced apoptosis, and caused mitochondrial damage and mtDNA release, activating the cGAS-STING-IRF3 pathway. Mechanistically, RNF185 mediated BAK1 ubiquitination to maintain mitochondrial integrity. Loss of RNF185 led to BAK1 accumulation and IRF3-dependent transcriptional upregulation of BAK1, forming a positive feedback loop promoting apoptosis. Knockdown of BAK1 or IRF3 rescued mitochondrial structure and cell survival. Honokiol, identified via molecular docking, targeted RNF185, reduced BAK1 ubiquitination, activated innate immune signaling, and inhibited tumor growth in vivo.

RNF185 sustains mitochondrial homeostasis and ESCC cell survival by promoting BAK1 ubiquitination and limiting cGAS-STING-IRF3-mediated immune activation. Targeting RNF185 with small molecules like Honokiol may represent a promising therapeutic approach in ESCC.